Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

New USPSTF Guidelines Increase Lung Cancer Screening Among African Americans

June 22nd 2022

The US Preventive Services Task Force updated its lung cancer screening guidelines in 2021 to include more members of vulnerable populations, including African Americans, women, and the LGBTQ community.

Capmatinib Approved in Europe for METex14-Altered Advanced NSCLC

June 22nd 2022

The European Commission has approved capmatinib as a single agent for the treatment of patients with MET exon14 skipping–altered advanced non–small cell lung cancer who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

FDA Grants Orphan Drug Designation to PT217 for SCLC

June 21st 2022

The FDA has granted an orphan drug designation to PT217 for use as a potential therapeutic option for patients with small cell lung cancer.

A Molecular Revolution Is Underway in Thoracic Oncology

June 20th 2022

Targetable alterations including BRAF V600E, EGFR exon 20 insertions, KRAS G12C mutations, MET exon 14 alterations, NTRK and RET rearrangements have taken up recent focus for investigators as data are pushing novel agents through the regulatory processes.

Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?

June 20th 2022

John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements.

Overcoming Barriers to Molecular Profiling in NSCLC Management

June 20th 2022

Expert perspectives on the prevalence of molecular profiling in NSCLC, and the unmet needs and barriers preventing the uptake of routine molecular testing.

Galinpepimut-S Plus Nivolumab Extends Survival in Malignant Pleural Mesothelioma

June 14th 2022

The combination of galinpepimut-S and nivolumab was found to extend survival in patients with malignant pleural mesothelioma who were either refractory to, or who had relapsed after, at least 1 line of standard therapy.

Adjuvant Atezolizumab Approved in Europe for High-Risk NSCLC With PD-L1 of ≥50%

June 14th 2022

The European Commission has approved atezolizumab for use as an adjuvant treatment following complete resection and platinum-based chemotherapy in adult patients with non–small cell lung cancer and a high risk of recurrence whose tumors do not have EGFR mutations or ALK alterations but have a PD-L1 expression of 50% or higher.

FDA Approval Sought for Adjuvant Pembrolizumab in Stage IB to IIIA NSCLC Following Surgical Resection

June 13th 2022

The FDA has accepted for review a new supplemental biologics license application seeking approval of pembrolizumab in the adjuvant treatment of patients with stage IB to IIIA non–small cell lung cancer after complete surgical resection.

NSCLC: The Role of Liquid Biopsy in Molecular Testing and Treatment Decision-Making

June 13th 2022

A brief discussion on insufficient tissue results in molecular profiling for NSCLC and how this can be avoided or addressed via liquid biopsy.

Testing Strategies for Actionable Mutations in Non–Small Cell Lung Cancer

June 13th 2022

Expert oncologist John Heymach, MD, PhD, provides comprehensive insight on testing strategies for actionable mutations in NSCLC.

First-Line Toripalimab Plus Chemotherapy Elicits Survival Benefit in NSCLC Irrespective of PD-L1 Status

June 9th 2022

Adding toripalimab to chemotherapy in the frontline setting demonstrated improved progression-free survival vs placebo plus chemotherapy in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.

Novel Chemoimmunotherapy Combinations Build on Established Treatment Standards in Lung Cancer

June 9th 2022

Lawrence E. Feldman, MD, discusses shifting standards of care in small cell lung cancer, plus the implications of the phase 3 LEAP-006 and LEAP-008 trials in non–small cell lung cancer.

Adagrasib Delivers Durable CNS-Specific Activity in KRAS G12C+ NSCLC

June 7th 2022

Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.

Afatinib Efficacy and Safety to Be Investigated in Metastatic Solid Tumors With NRG1 Fusions

June 7th 2022

Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.

Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%

June 7th 2022

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.

Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion Cancers

June 7th 2022

Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.

Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLC

June 7th 2022

Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.

Sugemalimab and Chemotherapy Displays Significant OS Improvement in NSCLC

June 7th 2022

Sugemalimab plus chemotherapy improved overall survival (OS) vs placebo plus chemotherapy in patients with newly diagnosed metastatic non–small cell lung cancer, irrespective of PD-L1 expression or tumor histology.

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

June 7th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.